Targeting nitrated proteins could lead to new cancer drugs
Glioblastoma multiforme is a type of cancer that develops in the brain. Aggressive and difficult to treat, tumors respond to few drugs, and most patients are treated with methods developed about 20 years ago. Kyle Nguyen, a second-year Ph.D. student in ’s laboratory at Oregon State University, has been looking for a new way to target these tumors. He will present on Friday, 3–3:15 p.m. EDT, at the 2021 ASBMB Annual Meeting.
In broad terms, the Franco lab is interested in the role of oxidative stress in diseases of the nervous system. Oxidative stress is a chemical imbalance inside cells that leads to an accumulation of oxidants that damage healthy cells. It has been linked to , including cancer. The lab studies the role of oxidants in the development and growth of tumors of the nervous system.
is the most powerful oxidant produced in cancer cells and in cells associated with other diseases. When peroxynitrite reacts with proteins it causes oxidative changes that can negatively affect the way the proteins work in the cells. “As far as we know, these are permanent chemical changes,” Nguyen said.
The lab is interested in tyrosine nitration, one of the changes mediated by peroxynitrite. Tyrosine nitration is virtually undetectable in normal tissues, Nguyen explained, so drugs that target nitrated proteins would not affect healthy cells. His project looked at tyrosine nitration of a protein called heat shock protein 90, or . Nitrated Hsp90 promotes the survival of tumor cells, and this role is mediated by nitration of tyrosine residues within this protein.
In his work, Nguyen shows that tyrosine nitration supports the survival and migration of glioblastoma cells and thus is important for tumor development, and that nitrated Hsp90 may play more than one role in these tumors. Non-tumor cells do not have nitrated Hsp90 and tumor cells do, so targeting nitrated Hsp90 or other nitrated proteins could selectively kill tumor cells with few side effects.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Transforming learning through innovation and collaboration
Neena Grover will receive the William C. Rose Award for Exemplary Contributions to Education at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.